Polyrizon Ltd - רווח לפני ניכוי ריבית, מסים, בלאי ופחת PLRZ

Polyrizon Ltd is scaling its business by selling intelligent intranasal drug delivery systems to major industry players. EBITDA cash flow reflects the current balance of demand, with the metric reaching 0.00. The licensing model for patent-protected barrier gels minimizes costs, ensuring positive FCF. Growth potential is supported by the expansion of the consumer base for personalized respiratory infection prevention.

This indicator reflects net cash flow from operating activities before accounting for tax liabilities and the cost of debt, allowing for an assessment of the business's fundamental efficiency. The EBITDA trend for Polyrizon Ltd. demonstrates the scientific model's ability to monetize biochemical developments in creating viral barriers, where the growth of this metric confirms the commercial success of innovations and justifies the costs of retaining scarce specialists.